1196 related articles for article (PubMed ID: 17161777)
41. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
42. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
43. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
Verdecchia P; Gentile G; Angeli F; Reboldi G
Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
[TBL] [Abstract][Full Text] [Related]
44. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
Andréjak M; Slama M; Hary L
Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
[TBL] [Abstract][Full Text] [Related]
45. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
46. [Pharmacological basis of antihypertensive drug therapy].
Kolck UW; Zaugg CE; Erne P
Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
[TBL] [Abstract][Full Text] [Related]
47. [Anti-atherosclerotic action of hypotensive drugs].
Gmiński J; Stajszczyk M
Wiad Lek; 1996; 49(7-12):182-98. PubMed ID: 9245114
[TBL] [Abstract][Full Text] [Related]
48. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
49. Additional small amounts of diuretics improve blood pressure control at low cost without disadvantages in blood sugar metabolism.
Kudoh T; Nagawaga T; Nakagawa I
Hypertens Res; 2008 Mar; 31(3):455-62. PubMed ID: 18497464
[TBL] [Abstract][Full Text] [Related]
50. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
[TBL] [Abstract][Full Text] [Related]
51. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers.
Winther K; Gleerup G; Hedner T
J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S41-4. PubMed ID: 1725542
[TBL] [Abstract][Full Text] [Related]
52. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
53. ACE inhibitor-based treatment and antihypertensive effects in patients with type 2 diabetes.
Jarmuzewska EA; Rocchi R; Guidoni A; Mangoni AA
Panminerva Med; 2008 Sep; 50(3):207-16. PubMed ID: 18927524
[TBL] [Abstract][Full Text] [Related]
54. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
55. Inhibiting the renin-angiotensin system: why and in which patients.
Berra K; Miller NH
J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
[TBL] [Abstract][Full Text] [Related]
56. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
57. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Gojanovic B; Feihl F; Liaudet L; Waeber B
J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):1-9. PubMed ID: 18404602
[TBL] [Abstract][Full Text] [Related]
58. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
59. Angiotensin-converting enzyme inhibition and fibrinolytic balance.
Matsumoto T; Horie M
Hypertens Res; 2011 Apr; 34(4):448-9. PubMed ID: 21326308
[No Abstract] [Full Text] [Related]
60. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
Cohen DL; Townsend RR
J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
